Cellceutix is a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of small molecule drugs to treat conditions such as drug-resistant cancers and autoimmune diseases. The company’s flagship compound is an anti-cancer drug, Kevetrin.
The company announced today that it is submitting an abstract for the upcoming 2013 American Socirty of Clinical Oncology Annual Meeting, which is to be held in Chicago, May 31 to June 4. The presentation is titled “A Phase 1 Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic Study of Thioureidobutyronitrile (Kevetrin), a Novel p53 Targeted Therapy in Patients with Advanced Solid Tumors.”
The meeting will give Cellceutix an opportunity to provide a comprehensive update on the latest data from the Kevetrin clinical trials to all interested parties. The meeting will showcase the accomplishments regarding Kevetrin since it was first introduced three years ago at the American Association for Cancer Research as a drug on the frontier of cancer research. Over those few days, there will also be a chance for company executives to interact with others and discuss future collaborations and studies.
The Chief Science Officer at Cellceutix, Dr. Krishna Menon, gave a preview. Menon stated, “We are still at the early stages of the clinical trial. To date, we have not observed any dose limiting toxicities. Initial pharmacokinetic data has been received, and is consistent with the animal data, which is a very optimistic sign going forward.”
For additional information about Cellceutix and Kevetrin, please visit www.cellceutix.com
Let us hear your thoughts below: